clinical trial award – preproposal due may 6, 2022

assistant professor level or above (or equivalent)

• preproposal submission is required; application submission is by invitation only.

• supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.

• proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.

• two options will be offered: o planning phase with clinical trial option: provides support to prepare and submit an investigational new drug/ investigational device exemption (ind/ ide) application to the u.s. food and drug administration (fda) and requires fda/regulatory approval or exemption to proceed before the clinical trial may be funded. o clinical trial only option: provides support for the clinical trial. ind or ide applications to the fda, if needed, must be approved by the fda and included in the application submission.

clinical trial:

• a funding limit is not defined; requested funding must be appropriate for the scope of work proposed.

• the maximum period of performance for the clinical trial is 4 years. planning phase with clinical trial option:

• the maximum allowable funding for the planning phase period of performance is $500,000 for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance for the clinical trial is 4 years.

discovery award – letter of intent due april 22, 2022

postdoctoral fellow or clinical fellow (or equivalent and above)

supports the exploration of a highly innovative new concept or untested theory.

• not intended to support the logical progression of an already established line of questioning.

• clinical trials will not be funded.

focused program award – preproposal due may 6, 2022

full professor level or above (or equivalent)

• preproposal submission is required; application submission is by invitation only.

• supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question.

• projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.

• projects may range from exploratory/ hypothesis-developing studies through small[1]scale clinical trials that together will address the overarching goal/question.

• research team of highly qualified, multidisciplinary project leaders should be led by an investigator with demonstrated success in directing large, focused projects

• ·        the maximum allowable funding for the entire period of performance is $7.2 million for direct costs.
• ·        indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·        the maximum period of performance is 4 years.

investigator-initiated research award – letter of intent due april 29, 2022

assistant professor level or above (or equivalent)

supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.

• partnering principal investigator option available.

• clinical trials will not be funded.

the maximum allowable funding for the entire period of performance is $1.6 million for direct costs for single investigators and $2.0 million for partnering investigators.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 4 years.

technology/therapeutic development award – letter of intent due april 29, 2022

assistant professor level or above (or equivalent)

• supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life.

• supports product-oriented projects (e.g., device, drug, clinical guidelines). the product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.

• two funding levels are available depending on the maturity of the product. the following are general descriptions, although not all[1]inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

o funding level 1: supports research that is supported by significant preliminary data but has not advanced to the level of clinical translation.

o funding level 2: supports research that is in the final states of preclinical development with potential for near-term clinical development. applications must provide relevant data that support the rationale for the proposed study. funding level 2 recipients must submit or obtain an ind/ide application to the fda, or must transition the product to clinical practice, within the period of performance.

• clinical trials will not be funded.

funding level 1:

• the maximum allowable funding for the entire period of performance is $2 million for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 4 years. funding level 2:

• the maximum allowable funding for the entire period of performance is $4 million for direct costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the pcarp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca  for additional information.

brain canada is pleased to be partnering with cancer research society to launch the brain canada – cancer research society translational research grants program. this funding opportunity will support basic researchers and clinicians as they work together to translate research into novel approaches for the study, diagnosis, and/or treatment of pediatric and adult brain cancer.

two grants of up to $1,000,000 each will be awarded through this new funding opportunity. successful teams must include the collaborative work of an early-career investigator and a senior investigator in either the basic and/or clinical research fields. 

evidence clearly shows that increasing equity, diversity, and inclusion (edi) in research environments enhances excellence, innovation and creativity. brain canada and cancer research society are committed to excellence through equity, and we encourage applicants of diverse backgrounds to apply to our funding opportunities.

click here to view the request for applications.

deadline to register: march 23, 2022 at 16:00 et

deadline for receipt of full applications: may 6, 2022 at 16:00 et

alliance international quantum grants will provide support for researchers in canada to establish and grow international research collaborations that will strengthen research excellence in canada and abroad, and further develop canadian research strengths and leadership in quantum science and technology. using nserc’s newly launched alliance international catalyst grants, alliance international catalyst quantum grants will provide up to $25,000 for one year to support canadian academic researchers in initiating and developing research collaborations with international researchers from the academic sector in the areas of quantum science and quantum technologies. it is expected that approximately 100 catalyst quantum grants will be awarded in fiscal year 2022–23. these grants will serve as the foundation for larger partnerships in later years.

proposals must focus on any of the following areas of quantum technologies:

• quantum algorithms/encryption
• quantum communications
• quantum computing
• quantum materials
• quantum sensing

collaborations that synergistically couple any of these quantum technology thrusts to other research topics in the natural sciences and engineering would be accepted.

please contact jill sherman, international research facilitator for more information at:  intl.research@lakeheadu.ca

the canadian bar law for the future fund (lfff) has grants available for innovative projects in the field of law.

projects eligible for consideration must be of national interest and/or of benefit to the general public and must be in at least one of the following fields:

• legal research
• legal education
• legislation and law reform
• administration of justice

lfff does not provide funding for capital projects, ongoing operating expenses, budget deficits, general fund drives, annual charitable appeals, scholarships, sabbaticals, conferences and seminars, nor applications relating exclusively to publication costs, equipment purchases or travel costs. no permanent commitments are made in support of a project, and no grants are made that would result in financial gain to an individual or organization

the goal of the mental health in the early years (mhitey) implementation science team grants funding opportunity is to fund implementation science research that enhances our understanding of how to improve the systematic and equitable implementation of evidence-based interventions for young children (i.e., girls, boys and gender diverse children ages 0-5) and their caregivers that address one or more of the following areas:

• promotion of positive socio-emotional development and mental health in early childhood;
• prevention of the development of early childhood mental health issues; and
• treatment of young children living with or at risk of developing mental health issues through integrated, coordinated and person-oriented care.

to accomplish this goal, the implementation science research will need to be person-oriented, engage relevant knowledge users as members of the research team, and prioritize health equity, indigenous rights, intersectionality and sgba+. the implementation science approach of this funding opportunity will improve our knowledge of how to implement and locally adapt early years mental health interventions across diverse settings and sectors with greater acceptability, wide-scale adoption, appropriateness, feasibility, fidelity, cost-effectiveness, penetration and sustainability. the resulting evidence will contribute to strengthened programs, services and policies for a more equitable, culturally safe, coordinated and integrated approach across a wide range of stakeholders to improve early years mental health promotion, prevention, treatment and care.

implementation science research can focus on evidence-based interventions (i.e., programs, services, policies) in formal and informal care settings, such as the home and the social care system, early years programming, indigenous early learning and childcare programs, indigenous language nests, daycare, preschool and kindergarten. interventions may also focus on the health care system, education system, social services, community and cultural organizations, public health and health professional services, and/or integration of care across two or more of these sectors. all interventions must target and evaluate mental health and/or socio-emotional development outcomes in young children ages 0 to 5. given the critical role that caregivers play in early childhood, interventions that include a perinatal and/or caregiver focus will also be eligible, as long as the outcomes of the intervention include enhanced mental health and wellbeing of children ages 0 to 5.

the forest sector investment and innovation program (fsiip) provides funding for strategic investments in the forest sector that:

• improve productivity and innovation
• enhance competitiveness
• support new market access
• provide benefits to ontario’s broader forest sector
• strengthen regional economies

support is available under two project categories – business projects and collaboration projects.

mhrc is proud to partner with the mitacs on this funding opportunity for canadian university & college 世界杯2022赛程表淘汰赛 across the country to work on a mental health research project with their academic supervisor and community partner.

the successful applicant will be awarded $15,000 for a four- or six-month term; funds will be paid directly to the student’s academic institution and held by the student’s supervisor. the project would begin in september 2022 and end by december or early february 2022. 

this jointly funded internship is part of mhrc’s 2022-2023 世界杯2022赛程表淘汰赛 hip cycle, where 世界杯2022赛程表淘汰赛 share their time between academic institutions and community service providers, tying together their research with the needs of the end-users — the community and people with lived experience. mhrc aims to drive systemic change by encouraging the adoption of effective, research-informed, and client-centric approaches to mental health treatment.

cira’s community investment program grants fund innovative community internet projects to build a resilient, trusted and secure internet for all canadians.